Amneal Pharmaceuticals, Inc. AMRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $423.24M-3.1% | $436.65M-5.2% | $460.74M+6.3% | $433.43M+4.5% | $414.71M-5.6% | |
| AvKARE | $166.02M-21.2% | $210.74M+6.1% | $198.53M+21.8% | $163.04M-5.4% | $172.42M+1.2% | |
| Specialty | $133.27M— | —— | $125.24M-2.2% | $128.04M+18.2% | $108.3M— | |
| Other Operating Income by Business | ||||||
| Affordable Medicines | $6.94M+694,000% | $1K-99.1% | $117K— | $0-100% | $5.12M— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | —— | $0— | $0— | $0— | |
| Gross Profit by Business | ||||||
| Affordable Medicines | $190.79M+26.5% | $150.79M-16.4% | $180.28M-0.3% | $180.78M+5.1% | $172.08M-3.4% | |
| AvKARE | $39.08M-8.5% | $42.7M+1.0% | $42.26M+27.2% | $33.23M+16.2% | $28.6M+21.8% | |
| Specialty | $90.25M-13.0% | $103.7M+102% | $51.43M-28.8% | $72.25M+30.9% | $55.21M-9.9% | |
| Operating Income (Loss) by Business | ||||||
| Affordable Medicines | $120.94M+47.5% | $82M-4.2% | $85.63M-16.4% | $102.38M-7.6% | $110.79M+20.6% | |
| AvKARE | $22.4M-12.3% | $25.53M-5.5% | $27.03M+49.0% | $18.15M+40.6% | $12.91M+73.1% | |
| Specialty | $50.06M— | —— | $9.57M-73.0% | $35.49M+137% | $14.99M— | |
| SG&A by Business | ||||||
| Affordable Medicines | $41.32M+10.9% | $37.27M+0.3% | $37.17M+8.6% | $34.23M+1.5% | $33.72M-0.6% | |
| AvKARE | $16.68M-2.8% | $17.17M+12.7% | $15.23M+1.0% | $15.08M-3.9% | $15.69M-2.0% | |
| Specialty | $34.69M— | —— | $33.58M+10.8% | $30.31M-2.1% | $30.98M— | |
| Gain (Loss) from Litigation Settlement by Business | ||||||
| Affordable Medicines | -$694K— | —— | —— | $390K— | —— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | —— | $0— | $0— | —— | |
| Other by Business | ||||||
| Affordable Medicines | $6.14M-2.6% | $6.3M-18.6% | $7.74M+6.6% | $7.27M+2.4% | $7.1M+4.1% | |
| Specialty | $905K+63.1% | $555K-78.2% | $2.55M+107% | $1.23M-1.4% | $1.25M+17.4% | |
| Acquisition costs by Business | ||||||
| Affordable Medicines | $0— | —— | —— | —— | —— | |
| AvKARE | $0— | —— | —— | —— | —— | |
| Specialty | $0— | —— | —— | —— | —— | |
| Restructuring and other charges by Business | ||||||
| Affordable Medicines | $0-100% | $2.2M+2,342% | $90K-86.8% | $683K— | $0— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $347K— | —— | $0-100% | $341K+162% | $130K— | |
| Currency translation by Business | ||||||
| Affordable Medicines | -$1.67M-252% | -$475K+67.5% | -$1.46M-1,505% | -$91K-249% | $61K+107% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | $0— | $0— | $0— | $0— | |
| Product development and studies by Business | ||||||
| Affordable Medicines | -$1M-114% | $7.25M+658% | -$1.3M-44.4% | -$900K+43.8% | -$1.6M— | |
| Specialty | $2.78M+177% | $1M-64.5% | $2.82M+19.1% | $2.37M+2.2% | $2.32M+150% | |
| Regulatory fees by Business | ||||||
| Affordable Medicines | $2.39M+109% | $1.15M-50.5% | $2.32M-21.0% | $2.93M— | $0-100% | |
| Specialty | $0— | $0— | $0— | $0— | $0— | |
| Cost of goods sold by Business | ||||||
| Affordable Medicines | $232.44M-18.7% | $285.86M+1.9% | $280.46M+11.0% | $252.65M+4.1% | $242.63M-7.1% | |
| AvKARE | $126.94M-24.5% | $168.04M+7.5% | $156.27M+20.4% | $129.81M-9.7% | $143.81M-2.1% | |
| Specialty | $43.02M— | —— | $73.81M+32.3% | $55.8M+5.1% | $53.08M— | |
| Materials and supplies by Business | ||||||
| Affordable Medicines | $8.82M+1.2% | $8.71M+39.8% | $6.23M-23.2% | $8.11M-4.9% | $8.53M-45.8% | |
| Specialty | $60K-93.9% | $986K-27.4% | $1.36M+202% | $450K+122% | $203K-45.3% | |
| R&D by Business | ||||||
| Affordable Medicines | $33.29M+18.8% | $28.01M-49.2% | $55.12M+31.6% | $41.9M+35.2% | $30.98M-36.3% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $5.1M— | —— | $8.23M+35.7% | $6.07M-33.1% | $9.06M— | |
| Goodwill by Business | ||||||
| Affordable Medicines | $158.02M-1.0% | $159.69M-0.3% | $160.17M-0.9% | $161.63M-0.1% | $161.72M0.0% | |
| AvKARE | $69.47M0.0% | $69.47M0.0% | $69.47M0.0% | $69.47M0.0% | $69.47M0.0% | |
| Specialty | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | |
| Employee compensation and benefits by Business | ||||||
| Affordable Medicines | $13.02M+6.4% | $12.24M-12.0% | $13.91M-5.4% | $14.69M+8.5% | $13.54M+19.9% | |
| Specialty | $11.94M+7.8% | $11.08M+0.9% | $10.97M+1.7% | $10.79M-0.7% | $10.87M+22.8% | |
| Facilities costs by Business | ||||||
| Affordable Medicines | $1.49M-9.8% | $1.65M-5.9% | $1.76M-2.1% | $1.79M+9.7% | $1.63M-5.5% | |
| Specialty | $35K-44.4% | $63K-84.6% | $409K-44.4% | $735K-2.0% | $750K-50.6% | |
| Milestones by Business | ||||||
| Affordable Medicines | $500K— | —— | $22.5M+254% | $6.35M+2,440% | $250K-97.5% | |
| Specialty | $0-100% | $3M— | $0— | $0-100% | $3M— | |
| Intellectual property legal development expenses by Business | ||||||
| Affordable Medicines | $1.49M+13.1% | $1.32M-44.5% | $2.38M+20.2% | $1.98M+15.5% | $1.71M-10.2% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $49K-46.2% | $91K+54.2% | $59K+51.3% | $39K-27.8% | $54K— | |
| Net revenue by Product | ||||||
| Auto-Injector | $41.91M+7.2% | $39.1M-50.5% | $78.94M+18.5% | $66.59M+38.3% | $48.16M+27.0% | |
| Biosimilar | $22.3M-24.2% | $29.43M+73.0% | $17.01M-32.6% | $25.25M-11.5% | $28.54M-26.0% | |
| Central nervous system | $83.38M-20.4% | $104.75M+34.9% | $77.63M-6.9% | $83.43M+23.4% | $67.61M-11.7% | |
| Distribution | $89.15M-17.2% | $107.68M+11.9% | $96.22M-3.5% | $99.66M-5.0% | $104.9M-1.5% | |
| Government label | $59.95M-30.9% | $86.79M-1.1% | $87.76M+93.2% | $45.42M-9.4% | $50.14M+7.0% | |
| Hormonal / allergy | $35.93M-24.6% | $47.63M+26.4% | $37.69M+6.4% | $35.42M+3.6% | $34.2M-7.6% | |
| Injectable | $49.94M+33.4% | $37.44M-31.1% | $54.37M+56.9% | $34.65M-0.4% | $34.79M-27.5% | |
| Institutional | $9.82M+17.1% | $8.38M+43.2% | $5.85M-42.2% | $10.13M-8.0% | $11.01M+2.6% | |
| International | $5.32M+96.9% | $2.7M-57.0% | $6.29M+231% | $1.9M+54.1% | $1.23M-4.6% | |
| Oral liquid | $12.09M-19.3% | $14.98M-8.7% | $16.42M-8.2% | $17.88M-24.1% | $23.55M-5.3% | |
| Oral solid | $171.1M-9.3% | $188.71M+4.6% | $180.46M+1.2% | $178.26M-0.4% | $178.95M-2.2% | |
| Other dosage forms | $46.61M-31.6% | $68.15M+14.2% | $59.66M-12.5% | $68.19M+20.8% | $56.42M-4.3% | |
| Other therapeutic classes | $13.95M-4.1% | $14.55M+46.6% | $9.92M+14.1% | $8.7M+34.1% | $6.49M-10.5% | |
| Subtotal dosage forms | $417.92M-3.7% | $433.95M-4.5% | $454.45M+5.3% | $431.52M+4.4% | $413.47M-5.6% | |
| Subtotal therapeutic classes | $133.27M-20.2% | $166.93M+33.3% | $125.24M-1.8% | $127.54M+17.8% | $108.3M-10.4% | |
| Transdermal | $73.96M+31.7% | $56.14M+17.9% | $47.6M+16.9% | $40.71M-5.5% | $43.06M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
